文献速递免疫规划传染病防控与疫情报告

BNT162b2(辉瑞-BioNTech)mRNA疫苗接种对12-18岁人群儿童多系统炎症综合征的有效性——美国,2021年7月至12月

Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-01-14

采用检测阴性病例对照设计,在美国20个州24家儿科医院评估12-18岁住院患者中,入院前≥28天接种2剂BNT162b2疫苗对儿童多系统炎症综合征(MIS-C)的有效性。共纳入102例MIS-C病例和181例住院对照,估计疫苗有效性为91%(95%CI=78%-97%)。所有38例需要生命支持的MIS-C患者均未接种疫苗。

要点

  • 2剂BNT162b2疫苗对12-18岁人群MIS-C的估计有效性为91%(95%CI=78%-97%)。
  • 所有38例需要生命支持的MIS-C患者均未接种疫苗。
  • 接种2剂BNT162b2疫苗与12-18岁人群对MIS-C的高水平保护相关。

核心结论

  • 接种2剂BNT162b2疫苗与12-18岁人群对MIS-C的高水平保护相关。
  • 所有38例需要生命支持的MIS-C患者均未接种疫苗,凸显所有符合条件儿童接种疫苗的重要性。

研究设计与样本

  • 采用检测阴性病例对照设计,纳入美国20个州24家儿科医院12-18岁住院患者。
  • 研究期间为2021年7月1日至12月9日,即大多数MIS-C患者可时间关联至SARS-CoV-2 B.1.617.2(Delta)变异株优势流行期。
  • 评估入院前≥28天接种2剂辉瑞-BioNTech疫苗对MIS-C的有效性。
  • 共纳入102例MIS-C病例和181例住院对照,对照包括检测阴性对照和综合征阴性对照两组,均与病例匹配。

主要发现

  • 2剂辉瑞-BioNTech疫苗对MIS-C的估计有效性为91%(95%CI=78%-97%)。
  • 所有38例需要生命支持的MIS-C患者均未接种疫苗。

关键数值与推荐

  • 2剂辉瑞-BioNTech疫苗对12-18岁人群MIS-C的估计有效性为91%(95%CI=78%-97%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after a typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3). In the United States, the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is currently authorized for use in children and adolescents aged 5-15 years under an Emergency Use Authorization and is fully licensed by the Food and Drug Administration for persons aged ≥16 years (4). Prelicensure randomized trials in persons aged ≥5 years documented high vaccine efficacy and immunogenicity (5),§ and real-world studies in persons aged 12-18 years demonstrated high vaccine effectiveness (VE) against severe COVID-19 (6). Recent evidence suggests that COVID-19 vaccination is associated with lower MIS-C incidence among adolescents (7); however, VE of the 2-dose Pfizer-BioNTech regimen against MIS-C has not been evaluated. The effectiveness of 2 doses of Pfizer-BioNTech vaccine received ≥28 days before hospital admission in preventing MIS-C was assessed using a test-negative case-control design¶ among hospitalized patients aged 12-18 years at 24 pediatric hospitals in 20 states** during July 1-December 9, 2021, the period when most MIS-C patients could be temporally linked to SARS-CoV-2 B.1.617.2 (Delta) variant predominance. Patients with MIS-C (case-patients) and two groups of hospitalized controls matched to case-patients were evaluated: test-negative controls had at least one COVID-19-like symptom and negative SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) or antigen-based assay results, and syndrome-negative controls were hospitalized patients without COVID-19-like illness. Among 102 MIS-C case-patients and 181 hospitalized controls, estimated effectiveness of 2 doses of Pfizer-BioNTech vaccine against MIS-C was 91% (95% CI = 78%-97%). All 38 MIS-C patients requiring life support were unvaccinated. Receipt of 2 doses of the Pfizer-BioNTech vaccine is associated with a high level of protection against MIS-C in persons aged 12-18 years, highlighting the importance of vaccination among all eligible children.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35025852. doi:10.15585/mmwr.mm7102e1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。